New drug SIBP-A19 tested in patients with advanced solid tumors
NCT ID NCT06990464
First seen Jan 11, 2026 · Last updated Apr 30, 2026 · Updated 16 times
Summary
This early-phase trial tests the safety and best dose of a new drug called SIBP-A19 in 156 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find the maximum tolerated dose and any side effects. Participants must provide tumor samples and meet other health criteria.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Union Hospital affiliated to Fujian Medical University
RECRUITINGFuzhou, Fujian, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.